Salutar Overview

  • Founded
  • 1983
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $55M
Latest Deal Amount

Salutar General Information


Designer of biomimetic drug with focus to magnetic resonance imaging, radioisotopic agents for diagnosis and therapy. The company is involved in research and development of contrast agents for magnetic resonance imaging.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Primary Office
  • 428 Oakmead Pkwy
  • Sunnyvale, CA 94086
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Salutar Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 28-Apr-1989 $55M 00.00 0000 Completed Generating Revenue
2. Early Stage VC 00.00 00.00 Completed Startup
1. Early Stage VC $600K $600K Completed Startup
To view Salutar’s complete valuation and funding history, request access »

Salutar Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Arthur Rock & Company PE/Buyout Minority 000 0000 000000 0
Hook Partners Venture Capital Minority 000 0000 000000 0
Mohr Davidow Ventures Venture Capital Minority 000 0000 000000 0
Sequoia Capital Venture Capital Minority 000 0000 000000 0
Venrock Venture Capital Minority 000 0000 000000 0
To view Salutar’s complete investors history, request access »